Overview: Herpes Simplex Virus 2 IgM TestIntroduction: The Herpes Simplex Virus 2 IgM Test detects IgM antibodies to HSV-2 to diagnose acute genital herpes, causing painful sores. Following 2023 IDSA guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, antiviral therapy, and improving outcomes in serology for patients with suspected acute HSV-2 infection, ensuring timely treatment to reduce severity and transmission.
Other Names: HSV 2 IgM Assay, Acute Genital Herpes Test.
FDA Status: FDA-cleared diagnostic test, meeting serology standards for diagnostic accuracy.
Historical Milestone: HSV-2 IgM testing began in the 1980s with herpes research. Immunoassays improved in the 1990s, enhancing acute infection detection.
Purpose: Diagnoses acute HSV-2 infection, guides antiviral therapy, and monitors anti-HSV-2 IgM in patients with painful genital sores.
Test Parameters: 1. HSV 2 IgM
Pretest Condition: No fasting required. Collect serum, CSF, or saliva at any time. Report symptoms like painful genital sores, fever, or neurological symptoms, and list medications.
Specimen: 2-5 mL serum (SST), 1-2 mL CSF (sterile container), or 1-2 mL saliva (sterile container). Centrifuge serum or CSF within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document painful genital sores, fever, or history of HSV-2 exposure. Include current medications, especially antivirals, and recent infections.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antiviral therapy or counseling.
Procedural Considerations: Uses an immunoassay to detect anti-HSV-2 IgM antibodies. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often for acute genital herpes diagnosis.
Factors Affecting Result Accuracy: Improper sample handling, early infection, or cross-reactivity with HSV-1 can affect results. False negatives may occur in very early infection.
Clinical Significance: Positive anti-HSV-2 IgM indicates acute HSV-2 infection, prompting antiviral therapy (e.g., acyclovir). Negative results may require repeat testing in early infection.
Specialist Consultation: Consult an infectious disease specialist or gynecologist for result interpretation and treatment planning.
Additional Supporting Tests: HSV-2 IgG, HSV PCR, or viral culture to confirm acute HSV-2 infection.
Test Limitations: False negatives may occur in early infection. Cross-reactivity with HSV-1 may complicate results. Clinical correlation is needed.
References: IDSA Herpes Guidelines, 2023; Clinical Infectious Diseases, Corey L, 2022.
